The objective of this study is to determine whether aprepitant blocks the opiate reward system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive first line therapy for early heroin abuse.
This initial proof-of-concept study focuses on evaluating whether an NK1 antagonist, aprepitant, can block opiate reward in non-dependent opiate experienced volunteers in response to a standard opiate challenge. Sixty subjects will be included in a randomized controlled study. Following a training challenge session, they will receive 1 week treatment with aprepitant or matching placebo, followed by a challenge session during which subjective and physiological responses to the opiate partial agonist buprenorphine will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Oral, 125 mg once daily for one week
Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
Karolinska University Hospital, Huddinge
Stockholm, Sweden
The primary outcome will be self-reported pleasurable opiate effect.
Time frame: One week
The secondary outcome will be physiological opiate responses.
Time frame: One week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.